drugset / Trial / NCT00960258
Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid Tumors.
NaSingle-groupOpen-labelTreatment
Summary
This study is to define the pharmacokinetics and to evaluate the safety of BAY73-4506, 160 mg once daily administered orally as a single agent in Japanese patients with advanced solid tumors.
Timeline
- Start
- 2009-07-01
- Primary completion
- 2010-04-26
- Completion
- 2013-11-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Regorafenib | Small molecule | 60 mg | Oral |
| Subject | Regorafenib | Small molecule | 120 mg | Oral |
| Subject | Regorafenib | Small molecule | 160 mg | Oral |